Patient demographics and baseline disease characteristics (MITT population: total N = 34)
| Demographic/characteristic . | Value . |
|---|---|
| Median age, y (range) | 64.5 (46-87) |
| Race, n (%) | |
| Asian | 2 (5.9) |
| Black of African heritage | 3 (8.8) |
| White | 29 (85.3) |
| Sex, n (%) | |
| Male | 17 (50.0) |
| Female | 17 (50.0) |
| ECOG status, n (%) | |
| 0 | 14 (41.2) |
| 1 | 13 (38.2) |
| 2 | 6 (17.6) |
| 3 | 0 |
| 4 | 1 (2.9) |
| Median time since first diagnosis, y (range) | 4.4 (0.9-12.8) |
| Prior multiple myeloma treatments | |
| Median no., (range) | 4.5 (2-10) |
| Lenalidomide, n (%) | 28 (82.4) |
| Thalidomide, n (%) | 27 (79.4) |
| Bortezomib, n (%) | 28 (82.4) |
| Demographic/characteristic . | Value . |
|---|---|
| Median age, y (range) | 64.5 (46-87) |
| Race, n (%) | |
| Asian | 2 (5.9) |
| Black of African heritage | 3 (8.8) |
| White | 29 (85.3) |
| Sex, n (%) | |
| Male | 17 (50.0) |
| Female | 17 (50.0) |
| ECOG status, n (%) | |
| 0 | 14 (41.2) |
| 1 | 13 (38.2) |
| 2 | 6 (17.6) |
| 3 | 0 |
| 4 | 1 (2.9) |
| Median time since first diagnosis, y (range) | 4.4 (0.9-12.8) |
| Prior multiple myeloma treatments | |
| Median no., (range) | 4.5 (2-10) |
| Lenalidomide, n (%) | 28 (82.4) |
| Thalidomide, n (%) | 27 (79.4) |
| Bortezomib, n (%) | 28 (82.4) |
MITT indicates modified intent to treat.